GeneOne’s DNA and RNA platforms allow for the rapid development of vaccines to combat emerging infectious diseases and the ability to design novel vaccines for established diseases. Leveraging the patented technology of our subsidiary, VGXI, GeneOne is well-positioned to manufacture large quantities of cGMP grade vaccines which may lower costs and improve accessibility of these life-saving medicines.

The diseases caused by emerging viruses are often some of the hardest to combat. In an outbreak situation, our platform allows rapid, flexible and specific vaccine design and fast, reliable manufacture.

Our DNA plasmid delivery technology can enable expression of recombinant proteins and monoclonal antibodies as therapeutic agents.

The target-specific gene inserts we design are carried in a safe DNA plasmid vector optimized to obtain stable expression within human cells. In contrast, current gene therapies in development typically use viral vectors that may have safety concerns and may not allow repeat courses of treatment due to immune responses against the viral vector.

Monoclonal antibody (mAb) therapies have proven effective in many areas such as cancers and autoimmune disorders. mAb production and purification is complex and costly. Plasmid DNA encoding monoclonal antibodies (Plas-mAbs®), streamlines product design and greatly simplifies manufacturing. Plas-mAbs have the potential to be more stable, more rapidly designed and manufactured, and more cost-effective than current cell-line derived monoclonal antibody therapies.

GeneOne is developing immunomodulatory small molecule drugs that can either stimulate immune responses to help prevent infection or suppress exaggerated ones to help ameliorate disease